Frankfurt
30.12.24
09:40 Uhr
0,193 Euro
-0,013
-6,31 %
-6,31 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SOLASIA PHARMA Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| APTORUM GROUP | 2,780 | 0,00 % | Why Aptorum Group (APM) Jumped Nearly 300% at Pre-Market Trading | ||
| AQUESTIVE THERAPEUTICS | 3,560 | 0,00 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update | Anaphylm (epinephrine) Sublingual Film pre-NDA meeting scheduled for fourth quarter 2024AQST-108 (epinephrine) Topical Gel pre-IND meeting scheduled for fourth quarter 2024Libervant® (diazepam) Buccal... ► Artikel lesen | |
| EYENOVIA | 0,148 | 0,00 % | EYENOVIA, INC. - 8-K, Current Report | ||
| TONIX PHARMACEUTICALS | 0,330 | 0,00 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces PDUFA Goal Date of August 15, 2025, for FDA Decision on U.S. Marketing Approval for TNX-102 SL for Fibromyalgia | Tonix received FDA's Day 74 Letter granting TNX-102 SL a Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025 TNX-102 SL is a non-opioid, centrally acting analgesic, granted Fast... ► Artikel lesen | |
| SHINECO | 4,530 | 0,00 % | SHINECO, INC. - 8-K, Current Report | ||
| OMNIAB | 3,540 | -0,56 % | OmniAb Reports Third Quarter 2024 Financial Results and Business Highlights | EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and nine months ended September 30, 2024, and provided operating and partner program... ► Artikel lesen | |
| NRX PHARMACEUTICALS | 2,200 | 0,00 % | NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Initial Section of U.S. New Drug Application to the FDA for NRX-100 (IV Ketamine) for the Treatment of Suicidal Depression | Aiming to be the first FDA-approved medication to treat suicidal depression
Designed to help address the needs of the more than 13 million Americans who seriously consider suicide... ► Artikel lesen | |
| BIONANO GENOMICS | 0,288 | 0,00 % | Bionano Genomics: Bionano Announces Amendment to Senior Secured Convertible Debentures in Debt Restructuring that Improves Cash Runway | ||
| CITIUS PHARMACEUTICALS | 4,000 | 0,00 % | Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update | Clinical and regulatory success in 2024 expected to drive value in 2025
CRANFORD, N.J., Dec. 27, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius... ► Artikel lesen | |
| HARROW | 33,530 | +0,43 % | Harrow Health Aktie: Stabile Aussichten? | Der Aktienkurs des Augenheilkunde-Spezialisten Harrow Health verzeichnete am 07. Dezember einen bemerkenswerten Anstieg von 5,08 Prozent auf 39,32 USD. Die Entwicklung steht im Kontrast zum negativen... ► Artikel lesen | |
| REVIVA PHARMACEUTICALS | 1,820 | 0,00 % | Reviva Pharmaceuticals: Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights | - 108 patients have completed 1-year of treatment in 1-year open-label extension (OLE) trial - - Vocal biomarker speech latency data from RECOVER trial reinforce brilaroxazine's improvement on negative... ► Artikel lesen | |
| VINCERX PHARMA | 0,262 | 0,00 % | Vincerx Pharma, Inc.: Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc. | PALO ALTO, Calif., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting... ► Artikel lesen | |
| ALLARITY THERAPEUTICS | 1,155 | 0,00 % | Allarity Therapeutics, Inc.: Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements | Two patients exceed 14 months on treatment in Phase 2 trial of advanced ovarian cancerAllarity maintains a cash balance of $18.5 million, sufficient to advance and accelerate stenoparib's clinical... ► Artikel lesen | |
| INHIBIKASE THERAPEUTICS | 3,250 | 0,00 % | Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity | -- Transformative Financing worth up to $275 million from Top-Tier Institutional Healthcare Investors -- -- Advancement of IkT-001Pro into a Late-Stage Clinical Trial Program in Pulmonary Arterial... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 13,320 | +2,23 % | Eton Pharmaceuticals Closes Acquisition of Increlex (mecasermin injection) | Acquisition bolsters Eton's commercial pediatric endocrinology portfolioProduct is now available through AnovoRx, a specialty pharmacy dedicated to serving patients with rare and chronic conditions... ► Artikel lesen |
SOLASIA PHARMA KK gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von -0,013 (-6,31 %) liegt der Kurs bei 0,193 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SOLASIA PHARMA KK finden Sie auf Wallstreet Online.
